Cystoscopy with TURBT (Transurethral Resection of Bladder Tumor)

• Send the base specimen SEPARATELY from the exophytic specimen. Staging requires detrusor muscle (muscularis propria) in the base sample — a combined specimen may prevent the pathologist from determining invasion depth. Label each specimen by anatomic location and document 'base with muscle submitted as separate specimen' in the operative note.
• Document tumor location by clock face and distance from the ureteral orifice. Tumors within 1 cm of the orifice alter management and should be documented: 'tumor located [X] cm from the [right/left] ureteral orifice.'
• Document irrigation fluid used. Monopolar resectoscope requires non-conducting electrolyte-free solution (glycine 1.5%, sorbitol, or mannitol). Bipolar resectoscope uses normal saline. Document explicitly — this is relevant if TUR syndrome is suspected postoperatively.
• Document intravesical instillation timing and agent. AUA 2024 guideline recommends single-dose intravesical chemotherapy (MMC 40 mg or gemcitabine 2 g) within 24 hours for low- and intermediate-risk NMIBC. Document the time from TURBT to instillation, dose, and that no perforation occurred. Contraindicated with confirmed or suspected bladder perforation.
• Document depth of resection and completeness. State whether the base included visually confirmed detrusor muscle, whether resection appeared complete, and whether any areas of concern for perforation were noted. Bladder perforation must be documented — extraperitoneal perforations are typically managed with catheter drainage alone; intraperitoneal perforations require operative repair and preclude intravesical instillation.

• TURBT code selection is by largest single tumor dimension: 52234 (small, 0.5-2.0 cm, 4.50 wRVU), 52235 (medium, 2.0-5.0 cm, 5.30 wRVU), 52240 (large, >5.0 cm, 7.31 wRVU). The 0.5 cm lower bound matters — fulguration of tiny papillary lesions <0.5 cm is integral to diagnostic cystoscopy and not separately billable. Document the largest tumor dimension explicitly in the operative note.
• Multiple tumors: for Medicare, bill the code corresponding to the single largest individual tumor — smaller tumors do not aggregate to a higher tier. Many commercial payers allow aggregate sizing (sum of multiple tumor dimensions); verify with payer before submitting aggregate claims.
• 52204 (cystoscopy with biopsy(s), 2.53 wRVU, 0-day global) covers biopsy without resection — use for CIS mapping biopsies, random surveillance biopsies, or when biopsy alone is performed at a separate distinct site. When biopsies are taken at sites distinct from the resected tumor at the same session, 52204 may be billed with modifier -59 (NCCI modifier indicator 1 — can be overridden with documentation). The biopsy site must be clinically distinct, not simply the resection margin.
• Global period is 0 days for all TURBT codes. There is no post-procedure global; follow-up cystoscopies and office visits are separately billable from the date of service.
• Blue light cystoscopy (Cysview/hexaminolevulinate): the add-on code is HCPCS C9738 (adjunctive blue light cystoscopy with fluorescent imaging agent, list separately with the base procedure). The drug itself is billed as HCPCS A9589 (hexaminolevulinate instillation, 100 mg) by the facility. C9738 is a facility-billable OPPS code; verify institutional policy. The drug is instilled intravesically 1 hour before the procedure.
• Fulguration of the tumor bed after resection is integral to 52234/52235/52240 — do not separately bill 52224 (cystoscopy with fulguration/treatment) for the same lesion. 52224 may be separately billed only when fulguration is performed for a distinct lesion not resected (e.g., residual CIS in a separate location after TURBT of the primary tumor at the same session) — document distinct site.
• Intravesical mitomycin C (MMC) or gemcitabine instillation: administer within 24 hours of TURBT for low- and intermediate-risk NMIBC per 2024 AUA/SUO guideline. Contraindicated if bladder perforation occurred, if extensive resection was performed, or if gross hematuria is present. The drug administration generates a separate pharmacy/nursing charge but does not add a separately billable surgical CPT code for the surgeon.
• Re-TURBT within 6 weeks is a strong AUA guideline recommendation for T1 disease, high-grade Ta, or when detrusor muscle is absent from the initial specimen. Document the rationale for re-TURBT; the repeat procedure is billed with the appropriate size-based code (52234/52235/52240) — global period is 0 days so no modifier is required for the repeat procedure.

General coding reference. Verify with your institution’s billing department before submitting claims.

ⓘ General Billing Tips →